March 11, 2020 / 12:40 PM / in 22 days

BRIEF-Millendo Therapeutics Expects Topline Results From Phase 2b Study Of Livoletide In Q2

March 11 (Reuters) - Millendo Therapeutics Inc:

* MILLENDO THERAPEUTICS REPORTS FULL YEAR 2019 OPERATING AND FINANCIAL RESULTS

* MILLENDO THERAPEUTICS - TOPLINE RESULTS FROM PIVOTAL PHASE 2B STUDY OF LIVOLETIDE IN PATIENTS WITH PRADER-WILLI SYNDROME EXPECTED IN EARLY 2Q20

* MILLENDO THERAPEUTICS - CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND RESTRICTED CASH WERE $63.5 MILLION AT DEC 31, 2019

* MILLENDO - TOPLINE RESULTS FROM FIRST COHORT OF PHASE 2B STUDY OF NEVANIMIBE IN PATIENTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA EXPECTED IN 2H20

* MILLENDO THERAPEUTICS INC - SUCCESSFUL FINANCINGS STRENGTHEN FINANCIAL POSITION, EXTENDING CASH RUNWAY INTO 2022

* MILLENDO THERAPEUTICS INC - EXPECTS TO BEGIN FIRST-IN-HUMAN STUDIES OF MLE-301 IN SECOND HALF OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below